LONGUEUIL, QC, Dec. 11, 2022 /CNW/ - Countries from around the world are getting ready to go back to the Moon, and Canada is playing a major part in this inspiring new endeavour. This morning at 2:38 a.m ET, two Canadian technologies launched on a SpaceX …
New York, New York--(Newsfile Corp. - December 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Rent the Runway, Inc. RENT pursuant and/or traceable to the Company's initial public offering …
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic …
New York, New York--(Newsfile Corp. - December 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of NewAge, Inc. NBEV NBEVQ between January 18, 2018 …
MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. IGMS, a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM's expanding portfolio of T …
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma 77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were …
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger …
Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) Graphite Bio, Inc. GRPH, a clinical-stage, next-generation gene editing company …
Detailed results from completed Phase 1b CIMON trial in 21 acute myeloid leukemia (AML) patients treated with the company's Microbiome Ecosystem TherapyTM (MET) oral capsule, MaaT033, demonstrating its safety and ability to increase gut microbiota …
– Kite's Manufacturing Time for Yescarta® in the U.S. is Median of 7-Days from Start of Cell Enrichment to Harvest, with an Overall 16-Day Turnaround Time (Leukapheresis to Product Release) – – CIBMTR Analysis Finds Median ‘Vein-to-Vein' Time ( …
– Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell therapy – – WU-NK-101 exhibited enhanced anti-tumor activity, robust bone marrow trafficking, and …
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL-2 inhibitor venetoclax in model of venetoclax-resistant AML KT-253 also active in other hematologic …
Vincerx's proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzumab ozogamicin) …
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML Additional presentations highlight Kronos Bio's collaboration with academic cooperative groups to better …
"Austin Accident Lawyer" Andrew Traub shares how his firm has helped their clients get past low insurance policy limits, and gave insights on how his firm has gotten past artificially low insurance caps that prevent injured clients from getting …
RADNOR, PA / ACCESSWIRE / December 11, 2022 / The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been against Rent the Runway, Inc. ("Rent the Runway") RENT. The …
New York, New York--(Newsfile Corp. - December 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Polished.com Inc. f/k/a 1847 Goedeker Inc. POL GOED: (i) pursuant and/or traceable to the …
RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS); Preclinical …
Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a single dose Data establishes preclinical proof of principle …
49% objective response rate (ORR) in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR) Even in patients who received prior CAR-T, 48% ORR and 32% CR observed in a dose expansion cohort from a Phase 1 …
